SlidesetHIVViral Hepatitis and Liver DiseaseRSVCOVID-19How to Improve Fruitful Dialogue between the Virology Lab and Clinicians (Lab Manager Perspective) - Francesca Ceccherini SilbersteinView Slideset
SlidesetHIVAbstract #1 Comparable Dynamics of Cell-Associated HIV-RNA, Total and Intact Proviral HIV-1 DNA in Virologically Suppressed People with HIV Switching to 2DR or Continuing 3DR Over an 18-Month Follow-Up - Lia FiaschiView Slideset
SlidesetHIVAbstract #2 In Addition to Their Ability to Induce Resistance to Antiretrovirals, Integrase Inhibitors and Lenacapavir Resistance Mutations Enable HIV-1 to Evade Recognition by the Innate Immune System - Elisa TeyssouView Slideset
SlidesetHIVAbstract #3 Unveiling Novel Microbiome Signatures for Natural Virological Control in HIV-1 Elite Controllers - Xiangning BaiView Slideset
SlidesetHIVAbstract #4 WG-am: A Novel Antiviral Dipeptide from Elite Controllers as a Promising Vaginal Microbicide for HIV Prevention - Rafael Ceña DiezView Slideset
SlidesetHIVAbstract #5 A French National Real-World Survey of People with Multi-Resistant HIV-1 Viruses Treated with an Antiretroviral Regimen Including Fostemsavir or Ibalizumab - Charlotte CharpentierView Slideset
SlidesetHIVAbstract #6 Lenacapavir Resistance Profile in Heavily Treatment-Experienced People in the PRESTIGIO Registry - Maria Mercedes SantoroView Slideset
SlidesetHIVAbstract #7 Resistance Analysis of Long-Acting Lenacapavir in Heavily Treatment-Experienced People with HIV After 3 Years of Lenacapavir Treatment - Nicolas MargotView Slideset
SlidesetHIVAbstract #8 Analysis of 16 Years of ARV Resistance Transmission in Newly Diagnosed HIV Cases in Spain (2007-2023): 2023 Update and the Impact of PrEP on M184V Detection - Paloma MuñozView Slideset
SlidesetHIVAbstract #9 Clearance of NNRTI Resistance-Associated Mutations in the HIV-1 DNA Reservoir with or Without the Presence of M184V Mutation - Anne-Geneviève MarcelinView Slideset
SlidesetHIVAbstract #10 Resistance Analyses of F/TAF, F/TDF, and Lenacapavir in the PURPOSE 1 and 2 Studies – Stephanie CoxView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseHow to Improve Fruitful Dialogue between the Virology Lab and Clinicians: Lab Manager Perspective - Francesca Ceccherini-SilbersteinView Slideset
SlidesetHIVAndrea de Luca Lecture: Biomedical Innovations in Drug Resistance Interpretation - Maurizio ZazziView Slideset
SlidesetHIVAbstract #11 Early Treatment Failure with Lenacapavir in HIV-2 Infection - Martin ObermeierView Slideset
SlidesetHIVAbstract #12 Increased Dynamics of Novel A6/B Recombinant Forms Emergence Following Full-Scale War in Ukraine - Karol SerwinView Slideset
SlidesetHIVAbstract #13 Estimating the Genetic Barrier for Resistance to Integrase Inhibitors for the Most Frequently Circulating HIV-1 Subtypes - Mafalda N.S. MirandaView Slideset
SlidesetHIVAbstract #14 Three-Years Outcome After Genotyping-Guided Switch in HIV Multi-Drug Resistant Patients in Cameroon: Evidence-Based Strategies for Achieving Epidemic Control in Low-and Middle-Income Countries - Ezechiel Ngoufack Jagni SemengueView Slideset
SlidesetHIVAbstract #15 Virologic Failure and Resistance Emergence During Treatment with B/F/TAF or DTG/3TC in PWH Without Prior Resistance Mutations: A Real-World Study - Thomas DrumelView Slideset
SlidesetHIVAbstract #16 APOBEC-Associated Mutations in HIV Drug Resistance: Challenges in Interpretation Using Next-Generation Sequencing - Federico GarcíaView Slideset
SlidesetHIVAbstract #17 Clonal Analysis of Near Full-Length Proviral HIV-1 Genome Enables Differentiation of APOBEC- and Drug-Resistant Populations in Highly Treatment Experienced People Living with HIV - Martin DäumerView Slideset
SlidesetViral Hepatitis and Liver DiseaseHCV Elimination: Why Do We Still Have Gaps and How Do We Close These Gaps? - Pavel KhaykinView Slideset
SlidesetViral Hepatitis and Liver DiseaseHCV Micro-Elimination Approaches: IV Drug Users – Spilios ManolakopoulosView Slideset
SlidesetViral Hepatitis and Liver DiseaseAbstract #19 Despite a Substantial Burden of HDV Infection, Gaps in HDV Screening Still Persists Across Europe: An Urgent Need to Strengthen Diagnostic Strategies at a Pan-European Level - Ilaria GrossiView Slideset
SlidesetViral Hepatitis and Liver DiseaseAbstract #20 Boosting HDV Testing in Spain through the Delta Double Reflex Strategy - Federico GarcíaView Slideset
SlidesetViral Hepatitis and Liver DiseaseAbstract #21 Viral Strain Networks Tracing Human or Environment-Linked Hepatitis E Virus Dispersion in Europe: HEV Molecular Signatures - Evelyne SchvoererView Slideset
SlidesetViral Hepatitis and Liver DiseaseUpdate Novel Biomarkers and Compounds in HBV/HDV - Valentina SvicherView Slideset
SlidesetViral Hepatitis and Liver DiseaseAbstract #22 Chronic HDV Co-Infection Is Characterized by a More Elevated Production of All Three HBsAg Isoforms Compared to HBV Mono-Infection, That Parallels HDV Replicative and Cytolytic Activity - Stefano D'AnnaView Slideset
SlidesetViral Hepatitis and Liver DiseaseAbstract #23 A High Degree of Genetic Variability Characterises HDV Sub-Genotypes 1 and Can Drive the Selection of Divergent Genetic Pathways Modulating HDV Replicative Potential and Cytolytic Activity - Lorenzo PiermatteoView Slideset
SlidesetViral Hepatitis and Liver DiseaseAbstract #24 HDV Molecular Epidemiology in Spain: Insights from Whole-Genome Sequencing - Marta Illescas LopezView Slideset
SlidesetViral Hepatitis and Liver DiseaseAbstract #25 Implementation of a Multicenter Reflex Testing Program for Hepatitis D Detection of and Registration of Positive Cases in Catalonia - Adriana PalomView Slideset
SlidesetCOVID-19Abstract #26 Global Burden of SARS-CoV-2 Infection, Hospitalization and Case Fatality Rate among COVID-19 Vaccinated Individuals and Its Associated Factors: A Systematic Review and Meta-Analysis - Aurelie Minelle Kengni NguekoView Slideset
SlidesetCOVID-19Long COVIDAbstract #27 Intra-Host Evolution of SARS-CoV-2 During Prolonged Infection - Alessia LaiView Slideset
SlidesetCOVID-19Abstract #28 Early Detection of SARS-CoV-2 Variants in a School Cohort Using Next-Generation Sequencing: Insights from the EUCARE Project - Ana AbecasisView Slideset
SlidesetCOVID-19Abstract #29 Evaluation of the SARS-CoV-2 Virus Genetic Barrier to Remdesivir and Nirmatrelvir In Vitro and In Vivo - Ilenia VarasiView Slideset
SlidesetHIVUpdate on the GS HIV Pipeline: A Focus on Treatment and Prevention – Calvin CohenView Slideset
SlidesetHIVTransmission Networks: Translation in Public Health Policies – Dimitrios ParaskevisView Slideset
